Home › Research › Treatments
Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antikörpers
Fortschritte der Neurologie · Psychiatrie, 2026-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Lecanemab ist eine Anti-Amyloid-Antikörper-Therapie, die entwickelt wurde, um toxische Amyloid-Plaques zu beseitigen und das Fortschreiten der Alzheimer-Krankheit zu verlangsamen. Belgische Forscher*innen versuchten mit Hilfe eines Alzheimer-Mausmodells die Mechanismen aufzudecken, die die Antikörper-induzierte Amyloid-Clearance antreiben. Publication History Article published online: 10 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
What this study adds
Evidence grade: Low
This report states that lecanemab is an anti-amyloid antibody therapy developed to remove toxic amyloid plaques and slow Alzheimer's progression. Belgian researchers used an Alzheimer's mouse model to investigate the mechanisms driving antibody-induced amyloid clearance, so the work is preclinical.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antikörpers. (2026). Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/a-2861-9919
Vancouver
Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antikörpers. Fortschritte der Neurologie · Psychiatrie. 2026. doi:10.1055/a-2861-9919.
BibTeX
@article{study2026-0681bd63,
title = {{Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antikörpers}},
journal = {Fortschritte der Neurologie · Psychiatrie},
year = {2026},
doi = {10.1055/a-2861-9919},
url = {https://doi.org/10.1055/a-2861-9919}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Lecanemab ist eine Anti-Amyloid-Antikörper-Therapie, die entwickelt wurde, um toxische Amyloid-Plaques zu beseitigen und das Fortschreiten der Alzheimer-Krankheit zu verlangsamen.
- Belgische Forscher*innen versuchten mit Hilfe eines Alzheimer-Mausmodells die Mechanismen aufzudecken, die die Antikörper-induzierte Amyloid-Clearance antreiben.
- Publication History Article published online: 10 June 2026 © 2026.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
This report states that lecanemab is an anti-amyloid antibody therapy developed to remove toxic amyloid plaques and slow Alzheimer's progression. Belgian researchers used an Alzheimer's mouse model to investigate the mechanisms driving antibody-induced amyloid clearance, so the work is preclinical.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 24 of the 93 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Fortschritte der Neurologie · Psychiatrie) |
| Journal's citation record | 0 / 4 | Fortschritte der Neurologie · Psychiatrie: journal h-index 48 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 24 of the 93 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.